Spruce Biosciences to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
SAN FRANCISCO--Spruce Biosciences (Nasdaq: SPRB), a biopharmaceutical company focused on therapies for rare endocrine disorders, will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference. CEO Richard King is scheduled to present on November 12 at 4:15 p.m. EST. Interested parties can access the live audio webcast from the company’s Investor Relations section, with a replay available for 30 days post-event. The company is developing tildacerfont to address classic congenital adrenal hyperplasia, a serious condition with no novel therapies approved in 50 years.
- None.
- None.
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that the company will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference.
Chief Executive Officer, Richard King, is scheduled to present on Thursday, November 12 at 4:15 p.m. EST.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.sprucebiosciences.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years.
